Electra, real VYEPTI patient
FIND AN INFUSION SERVICE PROVIDER IN YOUR AREA.
You are about to leave the VYEPTI website for healthcare professionals
VYEPTI Dosing and Administration Video Coming Soon
By leaving this page, all selections will be lost. Do you want to continue?
UNLEASH THE POWER OF VYEPTI
“My whole world opened up…”
Powerful migraine prevention*
*In patients who have 8 or more monthly migraine days.1 One month was defined as 28 consecutive days.2
“The migraine attacks were debilitating. I couldn’t function.”
Meet Electra†‡
Age: 37 years old
Sex: Female
Diagnosis: Chronic migraine
Treatment Concerns: Increasing use of acute medications
Impact: Missing work and time with family
†A real VYEPTI patient. Patient results may vary. VYEPTI may not work for everyone. Electra was compensated for sharing her story.
‡This patient profile may represent some of the healthcare challenges that could be encountered during typical clinical practice. Symptoms and responses to any treatment may vary. As always, use your clinical judgment.
Migraine had taken over Electra’s life
- Eight or more migraine days a month
- Migraine with nausea, light sensitivity, and mental fog
- Disruption of family life
- Inability to plan ahead
- Missed work days
“The migraine attacks were debilitating. I couldn’t function.”
She was losing hope
- Acute medications required with greater frequency
- Occasional need to visit the emergency room
- Tried >2 preventive treatments
- Stopped treatments due to lack of efficacy and/or side effects
“I love the IV… It’s easy to just get this once every 3 months and then be on my way.”1
VYEPTI is administered as one 30-minute IV infusion every 3 months.1
Watch Electra’s video to learn more about her life with migraine
AHS Symposium Cut V 12LR
Consider VYEPTI for your patients like Electra
With one 30-minute IV every 3 months, VYEPTI has the potential to help some patients overcome challenges associated with migraine.1
Learn more about VYEPTI in chronic migraine
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
References:
- VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
- Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365-e1377.
© 2022 Lundbeck. All rights reserved. VYEPTI, VYEPTI CONNECT, and VYEPTI GO are registered trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100032v9
This website is intended for US healthcare professionals only.
